

# 3rd Asian Urological Oncology Forum & 12th Annual Meeting of TUOA

Time : 2020/01/03-04(Friday & Saturday)

Venue : Howard Plaza Hotel Kaohsiung 7F Golden Dragon Hall

Host Organization : Taiwan Urological Oncology Association

Online registration : <https://bit.ly/2WyOoXv>



**[Day 1] : 2020/01/03(Friday) 14:00-19:00**

Time	Topic	Speaker
14:00-14:10	Opening	Po-Hui Chiang, President of TUOA, Taiwan
<b>Controversial issue on treatment strategy for urological cancer</b>		
<b>Challenge of current guideline</b>		
<b>Moderators:</b> Jacob See-Tong Pang (馮思中), LinKou Chang Gung Hosp., Taiwan Tsan-Jung Yu(余燦榮), E-DA Hospital, Taiwan Yen-Ta Chen(陳彥達), Kaohsiung Chang Gung Hosp., Taiwan Yuan-Tso Cheng(鄭元佐), Kaohsiung Chang Gung Hosp., Taiwan		
14:10-14:20	Partial nephrectomy for renal calyceal cancer	Chian-Shiu Chien(錢家陞), Yunlin Chang Gung Hosp., Taiwan
14:20-14:30	Total ureterectomy as a treatment strategy for ureteral cancer.	Chih-Hsiung Kang(康智雄), Kaohsiung Chang Gung Hosp., Taiwan
14:30-14:40	Evidence about upfront use of current mPC agent	Kevin Lu(盧嘉文), Taichung Veterans General Hosp., Taiwan
14:40-14:50	The role of metastasectomy for mRCC	Cheng-Kuang Yang(楊晨洸), Taichung Veterans Gen. Hosp., Taiwan
14:50-15:05	Discussion	
<b>Special issue of Uro-Oncology</b>		
<b>Moderators:</b> Hung-Jen Wang(王弘仁), Kaohsiung Chang Gung Hosp., Taiwan Edmund Chiong, Nat. Uni. Hosp., Singapore Yung-Shun Juan(阮雍順), Kaohsiung Med. University Hosp., Taiwan		
15:05-15:15	A multidisciplinary approach for optimizing treatment of urological cancer in the era of precision oncology	Po-Hui Chiang(江博暉), Kaohsiung Chang Gung Hosp., Taiwan
15:15-15:25	How to train and educate the young urologists and manage the Malaysian Urology Association	Clarence Lei Chang Moh, Normah Medical Specialist Centre in Kuching., Malaysia
15:25-15:35	Neoadjuvant therapy for high-risk prostate cancer	Chikara Ohyama, Hirosaki Uni., Japan
15:35-15:50	Discussion	
15:50-16:00	Coffee break	

Time	Topic	Speaker
<b>Prostate cancer section-1</b>		
<b>Moderators:</b> Chikara Ohyama, Hirosaki Uni., Japan Hanjong Ahn, Asan Medical Center, Korea Chien-Hui Ou(歐建慧), National Cheng Kung Uni., Hosp., Taiwan Hong-Chiang Chang(張宏江), Nat. Taiwan Uni., Taiwan		
16:00-16:10	Recent Update of nmCRPC	Ji Youl Lee, Catholic Uni., Korea
16:10-16:20	The bone management in prostate cancer medical treatment, including cancer treatment induced bone loss and SRE/SSE	Kazuhiro Suzuki, Gunma University Heavy Ion Med. Center, Japan
16:20-16:30	Focal HIFU: who is the best candidates? Experience from South Korea	Hak Min Lee, Seoul National University Bundang Hospital., Korea
16:30-16:40	Salvage HIFU, cryoablation or RT after primary treatment of PCA	Yi-Yang Liu(柳易揚), Kaohsiung Chang Gung Hosp., Taiwan
16:40-16:50	Human resilience in quality of life: recent health utility studies from long-term survivors of prostate cancer	Chang Wook Jeong, Seoul National University, Korea
16:50-17:00	The combined artesunate and antiandrogen treatment in castration-resistant prostate cancer with expressed androgen receptor splice variant 7 (AR-V7)	Byong Chang Jeong, Sungkyunkwan University, Korea
17:00-17:20	Discussion	
<b>Prostate cancer section-2</b>		
<b>Moderators:</b> Ryoichi Shiroki, Fujita Health University., Japan Seong Soo Jeon, Sungkyunkwan University, Korea Yen-chuan Ou(歐宴泉), Tong Gen. Hosp., Taiwan Chun-Te Wu (吳俊德), Keelung Chang Gung Hosp., Taiwan		
17:20-17:30	Prognostic significance of AR amplification in cell-free DNA of castration-resistant prostate cancer patients.	Shinichi Sakamoto, Chiba University, Japan
17:30-17:40	Tailorized Management of Prostate Cancer	Bannakij Lojanapiwat, Chiang Mai Uni., Thailand
17:40-17:50	Time to biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer	Hanjong Ahn, Asan Medical Center, Korea
17:50-18:00	The interaction of sex hormones, oxidative stress, phthalate in patients with elevated serum PSA	Yuh-Shyan Tsai(蔡育賢), National Cheng Kung Uni., Hosp., Taiwan
18:00-18:10	Projections of incidence and mortality of prostate cancer in Korea	Jae Young Joung, National Cancer Center, Korea
18:10-18:20	Current situation of prostate cancer management in Cambodia	Soarawee Weerasopone, Royal Phnom Penh hospital, Cambodia
18:20-18:40	Discussion	
18:40-18:50	Closing	Po-Hui Chiang, President of TUOA, Taiwan
19:00~	Gala Dinner	

※ TUOA 第六屆理監事選舉投票時間：2020年1月3日(五) PM 15:00~18:00

開票作業：PM 18:00~19:00

※ 學分申請：台灣泌尿科醫學會、台灣外科醫學會、中華民國癌症醫學會

**【Day 2】 : 2020/01/04(Saturday) 08:00-13:30**

Time	Topic	Speaker	Moderator
08:00-08:10	Opening remarks	Po-Hui Chiang, President of TUOA, Taiwan Seong Soo Jeon, President of KUOS, Korea Chikara Ohyama, Hirosaki Uni., Japan Bannakij Lojanapiwat, Chiang Mai Uni., Thailand Vu Le Chuyen, President of VUNA., Vietnam Clarence Lei Chang Moh, Normah Hospital, Kuching, Malaysia Edmund Chiong, Nat. Uni. Hosp., Singapore	
<b>Challenging urologic cancer-case sharing</b> <b>Moderators:</b> Jin Seon Cho, Hallym University, Korea Shao-Kuan Chen(陳紹寬), Cathay Hosp., Taiwan Ching-Chia Lee(李經家), Kaohsiung Med. Uni., Taiwan			
08:10-08:20	Uterine recurrence of bladder cancer after renal pelvic recurrence post total cystectomy and ileal conduit.	Akinori Takei, Chiba University, Japan	
08:20-08:30	Neoadjuvant treatment of locally advanced upper tract urothelial carcinoma	Won Sik Ham, Yonsei University, Korea	
08:30-08:40	Salvage prostatectomy for recurrent prostate cancer after local treatment	Sheng-Chen Wen(溫聖辰), Kaohsiung Med. Uni., Taiwan	
08:40-08:50	En-bloc vs conventional resection of bladder cancer: single surgeon experience	Ping-Chia Chiang(江品葭), Kaohsiung Chang Gung Hosp., Taiwan	
08:50-09:00	Case sharing of robotic radical nephrectomy for locally advanced renal cancer	Kai-Jie Yu(虞凱傑), LinKou Chang Gung Hosp., Taiwan	
09:00-09:10	Comparisons of cancer detection rate and complications between transrectal and transperineal prostate biopsy approaches	Guan-Lin Huang(黃冠霖), Fangliao general Hosp., Taiwan	
09:10-09:25	Discussion		
<b>Renal Cell Carcinoma</b> <b>Moderators:</b> Cheol Kwak, Seoul National University, Korea Wen-Jeng Wu(吳文正), Kaohsiung Med. University Hosp., Taiwan Shian-Shiang Wang(王賢祥), Taichung Veterans General Hosp., Taiwan			
09:25-09:35	The surgery for RCC with IVC thrombus	Tsunenori Kondo, Tokyo Women's Medical University, Japan	
09:35-09:45	Role of anti-PD-1 in patients with mRCC who received previous TKI therapy	Minyong Kang, Sungkyunkwan University, Korea	
09:45-09:55	Robotic-Assisted Partial Nephrectomy	Ryoichi Shiroki, Fujita Health University., Japan	
09:55-10:05	HALS partial nephrectomy: How I do it	Jae Young Park, Korea University, Korea	
10:05-10:15	Robot-assisted IVC thrombectomy: Different techniques according to side	Sung-Hoo Hong, Catholic University of Korea	
10:15-10:30	Discussion		
10:30-10:45	Coffee break		

Time	Topic	Speaker	Moderator
<b>Urothelial carcinoma</b>			
<b>Moderators:</b> Tsunenori Kondo, Tokyo Women's Medical University, Japan Dong Hyeon Lee, Ewha Women's University, Korea Min-Che Tung(童敏哲), Tung Gen. Hosp., Taiwan			
10:45-10:55	Experience in Robotic Assisted Radical Cystectomy	Vu Le Chuyen, President of VUNA Binh Dan Hospital., Vietnam	
10:55-11:05	Role of Lymph node dissection in UTUC - Defining the Boundaries	Edmund Chiong, Nat. Uni. Hosp., Singapore	
11:05-11:15	Effect of neoadjuvant chemotherapy on Ki67 and PDL1 expression in muscle-invasive bladder cancer	Shingo Hatakeyama, Hirosaki Uni., Japan	
11:15-11:25	Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey	Sun Il Kim, Ajou University, Korea	
11:25-11:35	PD-L1 is a good predictor of prognosis in upper tract urothelial carcinoma	Tsai-Mu Yao(蔡牧堯), Kaohsiung Med. University Hosp., Taiwan	
11:35-11:50	Discussion		
<b>Lunch symposium: Current evidence review</b>			
<b>Moderators:</b> Chi-Ping Huang(黃志平), China Medical University Hosp., Taiwan Shao-Chuan Wang(王紹全), Chung Shan Medical University Hosp., Taiwan Pai-Fu Wang(王百孚), Changhua Christian Hosp., Taiwan			
11:50-12:00	DNA damage repair and the role of PARP inhibitor in prostate cancer	Chia-Hao Hsu(許家豪), Lotung Poh-Ai Hosp., Taiwan	
12:00-12:10	Real-World evidence of Votrient on 1st line mRCC treatment	Hao-Han Chang(張顥瀚), Kaohsiung Med. University Hosp., Taiwan	
12:10-12:20	Evolving treatment strategy for immunotherapy in mUC - combination or monotherapy?	Yuan-Tso Cheng(鄭元佐), Kaohsiung Chang Gung Hosp., Taiwan	
12:20-12:30	New development in first line RCC with immuno-oncology	Yu-Chen Chen(陳妤甄), Kaohsiung Med. University Hosp., Taiwan	
12:30-12:40	Immunotherapy in RCC under taiwan healthcare system	Hui-Ying Liu(劉惠瑛), Kaohsiung Chang Gung Hosp., Taiwan	
12:40-12:50	The first choice matters: PSA response in mCRPC	Po-Yen Chen(陳柏諺), Kaohsiung Chang Gung Hosp., Taiwan	
12:50-13:00	Cardiovascular risk in androgen deprivation therapy	Chia-Hung Tsai(蔡佳宏), Kaohsiung Chang Gung Hosp., Taiwan	
13:00-13:20	Discussion		
13:20-13:25	Closing	Po-Hui Chiang, President of TUOA, Taiwan	
13:25-13:45	Annual member meeting of TUOA		
14:30-17:00	Pipe organ concert at Weiwuying National Kaohsiung Center for the Arts		
18:30	Dinner (For invited only)		